公司概覽
業務類別 Diagnostics & Research
業務概覽 Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
公司地址 13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753
電話號碼 +1 650 980-9190
傳真號碼 +1 650 456-2122
公司網頁 https://www.natera.com
員工數量 6140
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Michael Brophy Chief Financial Officer and Principal Accounting Officer 美元 562.79K 23/04/2026
Mr. Daniel Rabinowitz Secretary and Chief Legal Officer -- 23/04/2026
Mr. Solomon Moshkevich President, Clinical Diagnostics 美元 504.65K 23/04/2026
Mr. John Fesko Co-President and Chief Business Officer 美元 504.65K 23/04/2026
Mr. Steven Leonard Chapman Director, Chief Executive Officer and Co-President 美元 853.71K 23/04/2026
 
董事會成員
董事會 職務 更新日期
Dr. Matthew Rabinowitz Executive Chairman of the Board 23/04/2026
Mr. Jonathan Sheena Director 23/04/2026
Dr. Monica Bertagnolli, M.D. Independent Director 23/04/2026
Ms. Ruth W. Brinkley Independent Director 23/04/2026
Dr. Rowan E. Chapman, PhD Independent Director 23/04/2026
Mr. Eric N. Rubino Director 01/04/2026
Mr. Herm Rosenman Independent Director 23/04/2026
Dr. James I. Healy, M.D.,PhD Independent Director 23/04/2026
Mr. Steven Leonard Chapman Director, Chief Executive Officer and Co-President 23/04/2026
Dr. Gail B. Marcus Independent Director 23/04/2026
Dr. Roy D. Baynes, M.D.,PhD Independent Director 23/04/2026
Mr. Roelof Frederik Botha Lead Independent Director 23/04/2026
 
所屬ETF (更新日期: 25/04/2026 03:40)
代號 名稱 佔比% 持有日期
IBBiShares Biotechnology ETF0.69%31/03/2026
IWPiShares Russell Mid-Cap Growth ETF0.62%31/03/2026
IWFiShares Russell 1000 Growth ETF0.37%31/03/2026
IWRiShares Russell Mid-Cap ETF0.36%31/03/2026
XBIState Street® SPDR® S&P® Biotech ETF0.32%31/03/2026
VHTVanguard Health Care ETF0.28%31/03/2026
ARKKARK Innovation ETF0.27%31/03/2026
JGROJPMorgan Active Growth ETF0.26%31/03/2026
FBTFirst Trust NYSE Arca Biotech ETF0.24%31/03/2026
SCHGSchwab US Large-Cap Growth ETF™0.19%31/03/2026
ARKGARK Genomic Revolution ETF0.16%31/03/2026
VONGVanguard Russell 1000 Growth ETF0.15%31/03/2026
GSLCGoldman Sachs ActiveBeta® US LgCp Eq ETF0.13%31/03/2026
ITOTiShares Core S&P Total US Stock Mkt ETF0.12%31/03/2026
SCHXSchwab US Large-Cap ETF™0.10%31/03/2026
VTVanguard Total World Stock ETF0.07%31/03/2026
IWBiShares Russell 1000 ETF0.07%31/03/2026
FMDEFidelity Enhanced Mid Cap ETF0.06%31/03/2026
SMLFiShares U.S. Small-Cap Eq Fac ETF0.06%31/03/2026
FXHFirst Trust Health Care AlphaDEX® ETF0.06%31/03/2026
 1    2    3    4    5    6    7    8    9    10    11  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.